Stocks Health care BIIB
NASDAQ · Health careBiogen Inc. (BIIB)
Biogen Inc. brought in $9.9B of revenue over the twelve months to March 31, 2026, up 1.2% from a year earlier. Net income was $1.4B, a net margin of 13.8%. Operating cash flow minus capital spending left $2.1B of free cash flow in fiscal 2025. At March 31, 2026 it held $3.4B in cash against $6.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.
Key facts about Biogen Inc.
- Net worth
- Biogen Inc. has a market value (market cap) of $33B at the latest share price, and shareholders' equity of $18.7B on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9.9B (+2.2% year on year), with net income of $1.3B. Over the 12 months to March 31, 2026: revenue $9.9B, net income $1.4B.
- Cash flow
- In fiscal 2025 operations brought in $2.2B of cash; after $153.8M of capital spending, free cash flow was $2.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 29, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Biogen Inc.'s next report is expected around October 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Biogen Inc. does
Biogen Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BIIB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.9B | $1.3B | $8.79 | $2.1B |
| 2024 | $9.7B | $1.6B | $11.18 | $2.7B |
| 2023 | $9.8B | $1.2B | $7.97 | $1.3B |
| 2022 | $10.2B | $3B | $20.87 | $1.1B |
| 2021 | $11B | $1.6B | $10.40 | $3.4B |
| 2020 | $13.4B | $4B | $24.80 | $3.8B |
Full financial statements: income, balance sheet and cash flow
Where BIIB ranks in Health care
Latest SEC filings
What Biogen Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026
- July 29, 2026
- July 1, 2026
- June 10, 2026
- June 10, 2026Exhibits 8-K/A
- June 5, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Activist stake changed SCHEDULE 13D/A
- May 14, 2026
- May 14, 2026Tender offer (amended) SC TO-T/A
What is BIIB worth? A DCF from its reported cash flow
Insider trades
What the people running Biogen Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $239.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Godbout SeanChief Accounting Officer | Exercised options | 27 | - |
| October 2, 2026 | Godbout SeanChief Accounting Officer | Shares withheld for tax | 8 | $1.8K |
| August 4, 2026 | Minor LloydDirector | Soldpre-planned (10b5-1) | 593 | $119.2K |
| August 3, 2026 | Minor LloydDirector | Soldpre-planned (10b5-1) | 593 | $120.6K |
| June 9, 2026 | Freire Maria CDirector | Received as pay | 2,005 | - |
| June 9, 2026 | Minor LloydDirector | Received as pay | 1,505 | - |
| June 9, 2026 | Pangalos Menelas NDirector | Exercised options | 2,370 | - |
| June 9, 2026 | Pangalos Menelas NDirector | Received as pay | 1,505 | - |
Who owns BIIB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 12.4% | August 6, 2026 |
| Primecap Management Co13G, passive | 10.2% | November 13, 2025 |
| Vanguard Capital Management13G, passive | 7.48% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,041 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 18,217,239 | +5,409,698 |
| BlackRock, Inc. | 15,985,736 | +11,135 |
| Primecap Management Co | 15,154,606 | +396,999 |
| Vanguard Capital Management LLC | 9,651,117 | +113,700 |
| State Street Corp | 7,344,327 | +176,405 |
| Vanguard Portfolio Management LLC | 6,604,936 | +73,209 |
| Geode Capital Management, LLC | 4,449,295 | +106,693 |
| Wellington Management Group Llp | 3,117,469 | +155,828 |
| Norges Bank | 2,580,033 | new |
| Morgan Stanley | 2,411,271 | +240,331 |
| Aqr Capital Management LLC | 1,936,859 | +13,302 |
| Jpmorgan Chase & Co | 1,823,140 | -192,869 |
| Invesco Ltd. | 1,803,944 | +58,689 |
| Amundi | 1,516,831 | +726,004 |
| Legal & General Group Plc | 1,493,289 | +143,457 |
| Northern Trust Corp | 1,429,490 | -17,089 |
| Boston Partners | 1,263,429 | -436,649 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,255,168 | -122,400 |
| Goldman Sachs Group Inc | 1,230,390 | +179,296 |
| Dimensional Fund Advisors LP | 1,148,568 | +69,449 |
Insiders
19 insiders reported holding 246,007 shares in total, about $55M at the last price.
| Holder | Shares |
|---|---|
| Alexander Susan HEVP Chief Legal Officer | 41,807 |
| Viehbacher ChristopherPresident and CEO, Director | 29,924 |
| Rowinsky Eric KDirector | 25,844 |
| Gregory GingerEVP, Human Resources | 22,359 |
| Murphy NicoleHead of Pharm Ops and Tech | 19,611 |
| Sherwin Stephen ADirector | 15,193 |
| Kramer RobinChief Financial Officer | 11,472 |
| Mantas Jesus BDirector | 11,263 |
| Izzar RachidHead of Global Product Strat. | 11,011 |
| Hawkins William ADirector | 10,365 |
Questions about BIIB
What does Biogen Inc. do?
Biogen Inc. is a company in the Health care sector, listed on NASDAQ as BIIB. Its shares trade on NASDAQ under the ticker BIIB.
What is Biogen Inc.'s net worth?
Biogen Inc. has a market value (market cap) of $33B at the latest share price, and shareholders' equity of $18.7B on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Biogen Inc. profitable?
Yes. Over the twelve months to March 31, 2026 it reported net income of $1.4B on revenue of $9.9B, a net margin of 13.8%.
How much revenue does Biogen Inc. make?
Over the twelve months to March 31, 2026 Biogen Inc. reported revenue of $9.9B. That is 1.2% more than a year earlier.
When did Biogen Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 5, 2026.
When is Biogen Inc.'s next earnings report?
Biogen Inc.'s next report is expected around October 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BIIB with
Follow BIIB
Get an email when Biogen Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BIIB: get an email when it filesWhere the numbers come from
Financial figures are the values Biogen Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.